IOVANCE BIOTHERAPEUTICS INC (IOVA) Stock Price, Quote, News and Overview
NASDAQ:IOVA - Nasdaq - US4622601007 - Common Stock - Currency: USD
IOVA Quote, Performance and Key Statistics
NASDAQ:IOVA (5/16/2025, 10:51:08 AM)
1.685
-0.07 (-4.26%)
The current stock price of IOVA is 1.685 USD. In the past month the price decreased by -42.67%. In the past year, price decreased by -82.81%.
IOVA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.73 | 322.10B | ||
| AMGN | AMGEN INC | 13.06 | 145.75B | ||
| GILD | GILEAD SCIENCES INC | 13.15 | 126.74B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 111.79B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.3 | 63.61B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.48B | ||
| ARGX | ARGENX SE - ADR | 95.85 | 34.35B | ||
| ONC | BEIGENE LTD-ADR | 5.7 | 24.68B | ||
| BNTX | BIONTECH SE-ADR | N/A | 22.27B | ||
| NTRA | NATERA INC | N/A | 20.36B | ||
| BIIB | BIOGEN INC | 7.85 | 18.21B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.21B |
Related stock screener links
About IOVA
Company Profile
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. The company is headquartered in San Carlos, California and currently employs 838 full-time employees. The company went IPO on 2008-06-20. The firm develops and delivers tumor infiltrating lymphocyte (TIL), therapies for patients with solid tumor cancers. Its lead product candidate, Amtagvi (lifileucel), is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. The firm also marketing Proleukin (aldesleukin), aninterleukin-2, or IL-2, product used in the Amtagvi treatment regimen. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings for solid tumor cancers. Amtagvi and Proleukin are part of a treatment regimen that also includes lymphodepletion. The firm is also developing next generation therapies using TIL, such as genetically modified TIL cell therapy.
Company Info
IOVANCE BIOTHERAPEUTICS INC
825 Industrial Road, 4th Floor
San Carlos CALIFORNIA 94070 US
CEO: Maria Fardis
Employees: 838
Phone: 16502607120
IOVANCE BIOTHERAPEUTICS INC / IOVA FAQ
What is the stock price of IOVANCE BIOTHERAPEUTICS INC today?
The current stock price of IOVA is 1.685 USD. The price decreased by -4.26% in the last trading session.
What is the ticker symbol for IOVANCE BIOTHERAPEUTICS INC stock?
The exchange symbol of IOVANCE BIOTHERAPEUTICS INC is IOVA and it is listed on the Nasdaq exchange.
On which exchange is IOVA stock listed?
IOVA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for IOVANCE BIOTHERAPEUTICS INC stock?
19 analysts have analysed IOVA and the average price target is 19.57 USD. This implies a price increase of 1061.15% is expected in the next year compared to the current price of 1.685. Check the IOVANCE BIOTHERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is IOVANCE BIOTHERAPEUTICS INC worth?
IOVANCE BIOTHERAPEUTICS INC (IOVA) has a market capitalization of 562.67M USD. This makes IOVA a Small Cap stock.
How many employees does IOVANCE BIOTHERAPEUTICS INC have?
IOVANCE BIOTHERAPEUTICS INC (IOVA) currently has 838 employees.
Is IOVANCE BIOTHERAPEUTICS INC (IOVA) expected to grow?
The Revenue of IOVANCE BIOTHERAPEUTICS INC (IOVA) is expected to grow by 81.52% in the next year. Check the estimates tab for more information on the IOVA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy IOVANCE BIOTHERAPEUTICS INC (IOVA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of IOVA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of IOVA, evaluating the profitability, health, valuation and growth aspects
- IOVANCE BIOTHERAPEUTICS INC (IOVA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- IOVANCE BIOTHERAPEUTICS INC (IOVA) Sales and EPS estimates to see what analysts future expectations are.
- IOVANCE BIOTHERAPEUTICS INC (IOVA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- IOVANCE BIOTHERAPEUTICS INC (IOVA) Insider and Institutional Ownership to learn about the owners and their transactions.
- IOVANCE BIOTHERAPEUTICS INC (IOVA) Stock Chart to make your own analysis
- IOVANCE BIOTHERAPEUTICS INC (IOVA) Latest news and press-releases to stay up to date.
Does IOVANCE BIOTHERAPEUTICS INC (IOVA) stock pay dividends?
IOVA does not pay a dividend.
When does IOVANCE BIOTHERAPEUTICS INC (IOVA) report earnings?
IOVANCE BIOTHERAPEUTICS INC (IOVA) will report earnings on 2025-08-06, after the market close.
What is the Price/Earnings (PE) ratio of IOVANCE BIOTHERAPEUTICS INC (IOVA)?
IOVANCE BIOTHERAPEUTICS INC (IOVA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.24).
What is the Short Interest ratio of IOVANCE BIOTHERAPEUTICS INC (IOVA) stock?
The outstanding short interest for IOVANCE BIOTHERAPEUTICS INC (IOVA) is 26.08% of its float. Check the ownership tab for more information on the IOVA short interest.
IOVA Technical Analysis
IOVA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to IOVA. IOVA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
IOVA Financial Highlights
Over the last trailing twelve months IOVA reported a non-GAAP Earnings per Share(EPS) of -1.24. The EPS increased by 31.11% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -40.88% | ||
| ROE | -52.39% | ||
| Debt/Equity | 0 |
IOVA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to IOVA. The Buy consensus is the average rating of analysts ratings from 19 analysts.
For the next year, analysts expect an EPS growth of 38.43% and a revenue growth 81.52% for IOVA